The combined data convinced the FDA that anifrolumab's effects warranted approval – a decision thought to reflect at least in part the pressing need for new treatment options for people with SLE.
Hosted on MSN1mon
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback